It was found that the EGR1 (0.6%) exhibited the highest mutation frequency followed by RRM2 (0.2%) and TPP1 (0.2%), while both SOCS2 and C11or54 did not show any mutations in prostate cancer samples (Figure 4A). This evidence concerns the gene TPP1 and prostate carcinoma.